What Is Tremfya, and Why Does It Matter? Tremfya (guselkumab) is a lab-made, dual-acting antibody medication that reduces inflammation by targeting the interleukin-23 (IL-23) protein and blocking a ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
Tremfya interacts with other biologic immunomodulator drugs, such as abatacept (Orencia) and canakinumab (Ilaris). Tremfya can also interact with tricyclic antidepressants (TCAs), such as ...
On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s disease. The findings demonstrated significant clinical remission and ...
Tremfya (guselkumab) has potential interactions with certain other medications, such as abatacept (Orencia) and paroxetine (Brisdelle, Paxil). Using Tremfya may also affect how your body responds to ...
TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...
TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of ...
Tremfya is a brand-name medication used to treat moderate to severe ulcerative colitis in adults by targeting a protein that reduces inflammation in the large intestine. Treatment with Tremfya ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results